In comparison, patients with high ICOSLG expression had an increased risk of arthralgia (33.9% vs. 8.3%, p = 0.02), colitis (22.6% vs. 0, p = 0.01), pancreatitis (17.7% vs. 0, p = 0.03), and skin reactions (50% vs. 16.7%, p = 0.01). This evidence concerns the gene ICOSLG and colitis.